SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

At present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared PD-1 monotherapy (SWOG 1801 regimen) to the PD-1/CTLA-4 combination (NADINA regimen) therapy. The SWE-NEO study aims to compare these two regimens, where the PD-1/CTLA-4 combination is potentially more effective, but also associated with more side effects.

Trial Details

NCT ID
NCT06794775
Phase
PHASE3
Sponsor
Hildur Helgadottir
Status
RECRUITING
Cancer Type
Melanoma
Locations (sample)
  • Gothenburg, Sweden|57.70716,11.96679
  • Lund, Sweden|55.70584,13.19321
  • Stockholm, Sweden|59.32938,18.06871

Key Eligibility Criteria

  • Participants must be at least 18 years of age.
  • Can provide a signed informed consent as described in the protocol, including compliance with the requirements and restrictions listed in the ICF a…
  • World Health Organization (WHO) Performance Status 0 or 1.
  • Patients must have

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →